Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

p>

Favorable Results in QTc Study for R788

The recently completed double-blind, double-dummy, randomized, positive and placebo controlled parallel study of the effects of R788 on QT/QTc intervals in healthy subjects showed a favorable result. Under a protocol pre-reviewed by the Food and Drug Administration, a total of 208 healthy volunteers were divided into four dosage groups and given in a parallel design either placebo, a standard dose of 100mg bid of R788, a super dose of 300mg bid of R788, or moxifloxacin, (known to elevate QT/QTc intervals in normal healthy adults). All participants were dosed for four days and were evaluated for changes from the time-matched baseline QT/QTc intervals using extractions from continuous Holter monitors. There were no significant effects on the QT/QTc intervals of participants in either the 100mg bid or the 300mg bid R788 dosage groups. As expected, the study found that participants in the moxifloxacin group experienced QT/QTc elevations.

Conference Call and Webcast Information:

Rigel will host a conference call today at 8:30 am EST (5:30 am PST) to discuss the company's business plans and programs. To access the live call, please dial 800-299-7098 (domestic) or 617-801-9715 (international) 10 minutes prior to the start time and use the passcode 29850656. A replay of the call will be available, in podcast format, at approximately 9:30 a.m. EST on February 3, 2009 until February 10, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 98995701. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About R
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, ... to its investment in development and manufacturing capabilities with ... Karl Mueller , Particle Sciences, Associate Director Clinical ... pace adding clean room square footage, equipment and staff ... clients.  The company now has over 6000ft 2 ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) ... Stem, the latest addition to its growing hip ... intended for use in total hip arthroplasty and ... Alpine was developed based ... ODEV,s engineers worked closely with a select team ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... regarding WellPoint Inc. (NYSE: WLP ), Tekmira ... (NYSE: ZTS ), Sanofi SA (NYSE: ... wealth members receive these notes ahead of publication. To ... http://www.analystsreview.com/6142-100free . , ,-- ,WellPoint Inc. Research Reports ,WellPoint ...
Breaking Medicine Technology:Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The use ... blood thinners is growing at a rapid pace, even ... mount in courts around the U.S., Bernstein Liebhard LLP ... Journal of Medicine, within a year of its 2011 ... Xarelto as warfarin, a blood thinner that has been ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... a large population-based study of randomly selected participants ... (MCI) occurred twice more often in individuals diagnosed ... association was only observed in middle-aged participants (50-65 ... association vanished. This study is published in the ... concept of MCI describes an intermediate state between ...
(Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... known that diabetes, one of the world’s leading debilitating diseases, ... 194 million adults worldwide. Therefore, there is a huge demand ... the patients. ,There are two types of diabetes: ... for approximately 5% of all the cases. This type is ...
... been used by a pediatric research team to scrutinize ... small defects that lead to genetic diseases //. ... detect these abnormalities, the new research may lead to ... that lead to mental retardation. ,“For years, ...
... in Australia have been linked to the work place each ... //and the University of Sydney has shown that about 1,600 ... asbestos, passive smoking, fumes and exhaust at work. Several cases ... a work related origin. ,Professor Lin Fritschi, lead ...
... are planning to demand the government to levy heavy tax ... mainly combat the nation's obesity epidemic. The issue mainly addresses ... of salt added to burgers and processed foods. The ... to obesity. Due to this the sales of soft drinks ...
... CHICAGO - Abnormal glucose metabolism, which occurs when the ... twice as common among patients //with chronic nerve dysfunction ... may be a risk factor for the condition, according ... in the August 2006 print issue of Archives of ...
... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
Cached Medicine News:Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 3Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 4Health News:Work Related Cancer on the Rise in Australia 2Health News:Abnormal Glucose Metabolism May Contribute to Chronic Nerve Disorder 2Health News:Care Workers Need Some Care Too 2
... Sterilized Diamond Tips are available as ... Tips are irradiated by gamma-rays for more ... certificate of sterilization, specifying the date of ... usepractical, no need to autoclave. SterilPack Diamond ...
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
... way to order tips. Each box contains 1000 ... which contains 200 tips (4 bags of 50 ... of 200 tips per pack. Bulk Packs are ... be opened for quick access to Gilsons Diamond ...
... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
Medicine Products: